|
|
|
| |
|
|
| |
The latest psychiatry news from News Medical |
|
|
|
 | | |  Semaglutide outperforms other GLP-1 drugs for weight loss in psychiatric populations A network meta-analysis of nine randomized controlled trials found that once-weekly semaglutide showed the largest estimated weight-loss effect among GLP-1 receptor agonists tested in adults with mental illness and obesity or related metabolic risk. The authors cautioned that the findings remain preliminary because the evidence base was small, heterogeneous, and largely indirect. | | | | |  Scientists trace severe irritability to the brain’s response to frustration This review identifies maladaptive responses to frustrative non-reward as a potential mechanism underlying clinically significant irritability, particularly in youth. Animal studies reveal conserved behavioral responses, while human research links frustration to altered neural activity and highlights opportunities for cross-species treatment research. | |
|
|
| | | | |  Obesity and dietitian societies have joined forces to issue a new consensus statement on recommendations surrounding use of obesity drugs for weight loss treatment. | | | | |  Published today in Schizophrenia Bulletin, a first-of-its-kind randomized controlled trial (RCT) from researchers at the University of California, San Francisco (UCSF), and funded in part by the National Institute of Mental Health (NIMH), adds to growing literature on the potential benefit of a ketogenic diet for treating psychotic disorders. | | | | |  The research, published in the journal Maturitas, links trauma experienced to the onset of the menopause up to 20 months earlier and an increase in hot flushes, depression and cardiometabolic health problems. | | | | |  The King's College London study, published in Nature Communications, offers insight into how long-term inflammation may contribute to cognitive decline in disorders such as Alzheimer's disease, aging, depression, and the lingering neurological effects of viral infections. | | | | |  For decades, treating depression has largely involved a difficult form of medical guesswork: prescribing one antidepressant after another in hopes that one will eventually help. | | | | |  In health care, it is often the smallest moments that carry the greatest meaning - a quiet conversation with a patient, a shared reflection with colleagues, or a hand held in silence. | | | | |  Parkinson's disease (PD) is the second most common form of neurodegenerative disease and afflicts more than ten million people worldwide. While current therapies address disease symptoms, they do not prevent the underlying neurodegeneration that drives the disease. | | | | |  Research identifies a neurodevelopmental spectrum for ADHD and autism, emphasizing genetic links and their impact on cognitive and educational outcomes. | | | | |  A new study from University Hospitals Connor Whole Health reports that an insurance-supported integrative oncology program resulted in clinically meaningful improvements in cancer-related symptoms like pain, stress, anxiety, depression, nausea, and fatigue. | | | | |  Parkinson's disease (PD) is the second most common form of neurodegenerative disease and afflicts more than ten million people worldwide. While current therapies address disease symptoms, they do not prevent the underlying neurodegeneration that drives the disease. | | | | |  Millions of people are facing physical, emotional and financial toll of cancer, a disease that claims more than 26 000 lives every day, according to a report released today by the World Health Organization (WHO). | | | | |  Researchers from the University of Pennsylvania, New York University and Penn's Linguistic Data Consortium have received a two-year, $4 million grant from the Wellcome Trust to develop a scalable, AI-powered platform for training mental health clinicians. | | | | |  A Molecular Psychiatry review shows that depression in Alzheimer’s and Parkinson’s disease may reflect disease-specific molecular, neurotransmitter, inflammatory, and circuit-level disruptions rather than standard depression biology alone. It argues that broad antidepressants often show limited efficacy in these patients and that future trials should use biomarkers, neuroimaging, and symptom profiling to guide targeted treatments. | |
|
|
|
|
|
|
|
